Prof. André Vis, a urologist at VUMC in Amsterdam, the Netherlands, presented the DUET study. This feasibility study evaluated the use of 177Lu-PSMA radioligand therapy alternated with radium-223 in patients with bone-metastatic, oligo-metastatic, hormone-sensitive prostate cancer after curative therapy. The presentation discussed the potential of this treatment approach in improving outcomes for patients in this setting.
With the educational support of:
